ClinicalTrials.gg
RecruitingNCT06164483Updated May 12, 2026

Auditory Functions in Patients With Multiple Sclerosis

An observational study in Multiple Sclerosis and Hearing Disorders, sponsored by University of Catania. Recruiting at 1 site in Italy. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by University of Catania · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.

Planned enrollment
56th of 59
30 · median 214
Started
2026
with 10 others
Observational
59 of 289
20 open now
Primary completion
2027-12
later than 73 of 89 live
Registered
232nd of 289
by date

Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 56th largest by planned enrollment of the 59 observational ones that give a count, is one of 11 that started in 2026, is one of 59 observational ones, reaches primary completion later than 73 of the 89 other live ones, and was the 232nd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in Multiple Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

The study will analyze the auditory functions of patients with Multiple Sclerosis using auditory tests like pure tone auditory test, speech perception test, Auditory Brain Response (ABR) and Distortion Product Otoacustic Emission (DPOAE). CSF will be collected by lumbar puncture and analyzed looking for inflammatory markers.

The results of DPOAE and CSF will be correlated to identify statistically significant correlation.

Read the detailed description

Case-Control study

Tools for patients' selection and inclusion in the study

STEP one

  • Full medical records detailed for neurological diseases
  • Brain and spinal cord MRI performed 12 months (n1) before and most recent one (n2)
  • Lumbar puncture
  • Blood test
  • Questionnaire for screening hearing disorders
  • App for screening hearing loss

STEP two

  • Pure Tone Auditory test + Tympanometry and Stapedial Reflex
  • Speech Perception test
  • In case of tinnitus: tinnitus questionnaire and acuphenometry
  • DPOAEs
  • ABR

STEP three in case of Hearing impairment

- MRI Tractography

03

Conditions studied

  • Multiple Sclerosis
  • Hearing Disorders
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy patients and patients with RRMS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >18 and \<50,
  • no history of hearing loss,
  • no psychiatric condition
  • no familial history of otosclerosis/deafness/genetic hearing loss
  • patients with PD and/or MS.

Exclusion criteria

Exclusion Criteria

  • Conductive hearing loss
  • stroke \< 2 years
  • cardiovascular disease non under control
  • diabetes
  • hypotensive disorders
  • alcohol abuse
  • recreational drug consumption
  • epilepsy
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Control

    Healthy patients between 20 and 40 years

    Diagnostic Test: Auditory test · Other: CSF sampling

  • MS group

    Patient with Relapsing Remitting MS age between 20 and 40 years

    Diagnostic Test: Auditory test · Other: CSF sampling

Interventions

  • Diagnostic testAuditory test

    The patients will perform: Pure Tone Auditory test + Tympanometry and Stapedial Reflex * Speech Perception test * In case of tinnitus: tinnitus questionnaire and acuphenometry * DPOAEs * ABR

  • OtherCSF sampling

    Cerebrospinal Fluid will be collected by lumbar puncture and analyzed

06

What researchers measure

Primary outcomes

  1. Auditory functions and correlation with CSF findings

    The worsening of the hearing thresholds and DPOAE results will be correlated with the presence of inflammatory elements in the CSF

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

Time frame: 24 months for 12 months

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 19 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
May 11, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06164483
Lead sponsor
University of Catania
Responsible party
Arianna Di Stadio (Associate Professor fixed time, University of Catania) — Principal investigator
First posted
Dec 11, 2023
Start date
May 11, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
May 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion